“Rheumatology as a specialty all the 70 years was to help patients with severe infections caused by COVID-19. Since most effective medications now used to treat these patients are not antiviral drugs that have yet to be developed, the range of drugs that were developed for the treatment of rheumatoid arthritis is an inhibitor of interleukin-6 and also, it is possible that inhibitors of tumor necrosis factor and Janus kinase – said academician of RAS, President of Russian public organization “Association of rheumatologists of Russia”, chief freelance specialist-rheumatologist of the Ministry of health of the Russian Federation Evgeny Nasonov speaking at the July 2 online press conference dedicated to new treatment options for rheumatoid arthritis (RA). — All the experience and expertise of rheumatology, suddenly was in demand in the face of this terrible pandemic, this call to humanity”.
According to Nasonova, the real breakthrough in rheumatology has been the emergence of this class of drugs as inhibitors of Janus kinases. He compared this event with the advent in 1948 of glucocorticoid hormones.
The emergence of modern oral therapy of RA dramatically increased treatment adherence, simplify therapy, says the academician. This applies to a new drug updatetime, recently registered in Russia. The conclusion of this drug on the Russian market was dedicated to the VI Summit of rheumatology, conducted by the Association of rheumatologists of Russia on 26-27 June online.
Rheumatoid arthritis is inflammatory autoimmune rheumatic disease of unknown etiology, characterized by chronic and erosive arthritis and systemic lesions of the internal organs, leading to early disability and reduced life expectancy of patients. Its prevalence is 0.5-1% of the population in Russia know about 850 thousand patients with RA. The disease affects all age groups. Up to 40% of patients with RA become disabled within 5 years of diagnosis and 50% within 10 years. More than half of patients with RA receiving treatment baseline anti-inflammatory drugs (with DMARD) and genetically engineered biological drugs (GIPB) do not achieve remission.